title: Lisuride in Parkinson's disease. 4-year follow-up.
abstract: Lisuride at a mean daily dose of 3 mg was given to 48 patients with idiopathic Parkinson's disease. Twenty received lisuride alone (Group A) and 36 received lisuride + L-Dopa + peripheral decarboxylase inhibitors (Group B). Dropouts were due primarily to lack of efficacy in Group A patients and to mental side effects in Group B patients. The patients who remained in the study for the full 4 years showed distinct improvement, which was maintained. Group A patients did not have the on-off phenomenon or abnormal involuntary movements.
authors.affiliation: Department of Neurology, Instituto Neurologico C. Besta, Milan, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Giovannini
authors.forename: G
authors.initials: G
authors.lastname: Scigliano
authors.forename: I
authors.initials: I
authors.lastname: Piccolo
authors.forename: P
authors.initials: P
authors.lastname: Soliveri
authors.forename: I
authors.initials: I
authors.lastname: Suchy
authors.forename: T
authors.initials: T
authors.lastname: Caraceni
mesh_terms: D000328:Adult; D000368:Aged; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008090:Lisuride / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D004873:Ergolines; D007980:Levodopa; D008090:Lisuride